Related Experiment Video
Updated: Jun 3, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with
1Onyx Pharmaceuticals, Richmond, CA.
Abstract:
Selectively replicating viruses may offer a new approach to cancer treatment. If successful in clinical trials, these agents will constitute a new category in the antitumoral armamentarium. Many viruses are currently being studied, and an adenovirus (ONYX-015) first entered clinical trials in 1996; herpesvirus agents are scheduled to enter clinical trials in 1998. Critical issues need to be addressed if the utility of these agents is to be optimized. For each virus, the effect of antiviral immunity on antitumoral efficacy must be better understood. For all viruses, physical barriers to spread within tumors (e.g., fibrosis, pressure gradients) must be overcome. Although proof-of-concept experiments with chemotherapy and ONYX-015 have been encouraging, further studies are required to determine optimal treatment-regimen sequencing. Combination studies with radiation therapy are also underway with ONYX-015. Finally, these agents may require modification (e.g., coat modification) in order to maximize effectiveness against systemic metastases following intravenous administration.
Insights
Selectively replicating viruses, like adenovirus (ONYX-015), show promise for cancer treatment. Further research is needed to overcome immunity and physical barriers for optimal efficacy.
Area of Science:
- Oncolytic virotherapy
- Viral oncology
- Cancer therapeutics
Background:
- Selectively replicating viruses represent a novel therapeutic strategy for cancer.
- Adenovirus (ONYX-015) and herpesvirus agents are under investigation for clinical application.
- Antitumoral armamentarium expansion with viral agents is a key research area.
Purpose of the Study:
- To explore the potential of oncolytic viruses as a new cancer treatment modality.
- To identify critical factors for optimizing the efficacy of viral cancer therapies.
- To address challenges related to antiviral immunity and tumor microenvironment barriers.
Main Methods:
- Review of ongoing clinical trials and preclinical studies of oncolytic viruses.
- Investigation of the impact of host antiviral immunity on viral antitumoral activity.
- Analysis of physical barriers within tumors affecting viral spread and efficacy.
- Evaluation of combination strategies with chemotherapy and radiation therapy.
- Consideration of viral vector modifications for enhanced systemic delivery and efficacy.
Main Results:
- Early clinical trials with adenovirus (ONYX-015) have shown encouraging proof-of-concept.
- Combination studies with chemotherapy and radiation therapy are in progress.
- Understanding and overcoming antiviral immunity is crucial for therapeutic success.
- Physical barriers within tumors impede viral dissemination and require mitigation strategies.
Conclusions:
- Oncolytic viruses hold significant potential as a new class of cancer therapeutics.
- Optimizing viral efficacy necessitates addressing host immunity and tumor microenvironment challenges.
- Further research into combination therapies and viral vector engineering is essential for clinical translation.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:11Clinical Trials: Overview